Tiziana Life Sciences has developed an investigational technology for the treatment of Covid-19.

The approach involves the use of a handheld inhaler or nebuliser to directly deliver anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs.

This is expected to support the company’s development of a fully-human anti-IL6R mAb, TZLS-501, to treat Covid-19.

Tiziana Lifesciences chairman Gabriele Cerrone said: “Direct delivery of anti-IL-6R mAb to the lungs using a portable handheld inhaler or nebuliser is a rapid and immediate therapy for children and adults infected with Covid-19.

“Importantly, this treatment with our fully human anti-IL-6R mAb (TZLS-501) has the potential to be a long-term therapy to halt progression and reduce mortality in patients with Covid-19, as a portion of the population may not opt to utilise a vaccine.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.